Vanguard Group Inc Galecto, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLTO
# of Institutions
21Shares Held
1.52MCall Options Held
100Put Options Held
100-
Jim Simons Renaissance Technologies LLC | New York, Ny579KShares$4.24 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA214KShares$1.57 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA168KShares$1.23 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il129KShares$941,2340.0% of portfolio
-
State Street Corp Boston, MA44.9KShares$328,7110.0% of portfolio
About Galecto, Inc.
- Ticker GLTO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,395,700
- Market Cap $186M
- Description
- Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...